SCHEMBL10106383

SCHEMBL10106383

CCc1cccc(C(O)(c2cc(C3OCC(C)(C)CO3)ccc2OC)c2cc(C3OCC(C)(C)CO3)ccc2OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
ALOX5 P09917 1/20 0.32
PTPN1 P18031 1/20 0.32
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
TAS1R2 Q8TE23 1/20 0.32
NR3C2 P08235 1/20 0.31
NR3C1 P04150 3/20 0.31
SLC5A1 P13866 1/20 0.31
SLC5A2 P31639 1/20 0.31
ACHE P22303 1/20 0.31
MAPK3 P27361 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106355 0.91 NPC1 (0.35) SMN1; SMN2RAB9ANPC1HTTKMT2A
SCHEMBL10106322 0.87 RAB9A (0.39) SMN1; SMN2RAB9ANPC1KMT2AALOX5
SCHEMBL10106336 0.86 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ANPC1LMNAHTT
SCHEMBL10106346 0.86 NPC1 (0.39) SMN1; SMN2RAB9ANPC1LMNAALOX5
SCHEMBL10330556 0.85 NR3C1 (0.33) SMN1; SMN2RAB9ANPC1NR3C2NR3C1
SCHEMBL10106311 0.84 NPC1 (0.34) SMN1; SMN2RAB9ANPC1
SCHEMBL10106377 0.82 NPC1 (0.34) SMN1; SMN2RAB9ANPC1
SCHEMBL10106372 0.82 NPC1 (0.34) SMN1; SMN2RAB9ANPC1
SCHEMBL10106337 0.82 EGFR (0.41) SMN1; SMN2RAB9ANPC1
SCHEMBL7074120 0.81 NPC1 (0.41) SMN1; SMN2RAB9ANPC1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-8119672-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-02-21 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML SMN1; SMN2 1044/4885RAB9A 2880/4885NPC1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.